Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.78 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.78 |
| ▸ | TNKS | O95271 | 7/20 | 0.73 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.73 |
| ▸ | PARP1 | P09874 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | GUSB | P08236 | 3/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.60 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28547770 | 0.98 | HPGD (0.97) | HPGDMAPTKDM4CTNKSTNKS2 | |
| SCHEMBL30527145 | 0.88 | KDM4C (1.00) | HPGDMAPTKDM4CTNKSTNKS2 | |
| SCHEMBL20320595 | 0.88 | KDM4C (1.00) | HPGDMAPTKDM4CTNKSTNKS2 | |
| Hydrochloric Acid SCHEMBL30002977 | 0.87 | KDM4C (0.97) | HPGDMAPTKDM4CTNKSTNKS2 | |
| Hydrochloric Acid SCHEMBL20303157 | 0.87 | KDM4C (0.97) | HPGDMAPTKDM4CTNKSTNKS2 | |
| SCHEMBL258433 | 0.85 | TNKS (1.00) | HPGDMAPTKDM4CTNKSTNKS2 | |
| SCHEMBL29592833 | 0.85 | TNKS (1.00) | HPGDMAPTKDM4CTNKSTNKS2 | |
| Hydrochloric Acid SCHEMBL31529601 | 0.84 | TNKS (0.96) | HPGDMAPTKDM4CTNKSTNKS2 | |
| SCHEMBL15966811 | 0.83 | HPGD (0.71) | HPGDMAPTKDM4CTNKSTNKS2 | |
| SCHEMBL14344501 | 0.83 | KDM4C (1.00) | HPGDMAPTKDM4CTNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941426-A1 | SUBSTITUTED PYRIMIDINE AMINOALKYL-QUINAZOLONES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Gilead Calistoga LLC (US) | 2015-11-11 | — | — | EP | claimed |
| WO-2014100765-A1 | SUBSTITUTED PYRIMIDINE AMINOALKYL-QUINAZOLONES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | WO | claimed |
| WO-2013130660-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | claimed |
| CN-112566906-A | Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 | 多曼治疗学公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2014128206-A1 | COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-28 | — | — | WO | disclosed |
| EP-2769723-A1 | Compounds for use in inhibiting HIV capsid assembly | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-27 | — | — | EP | disclosed |
| CN-103408502-A | Synthetic method of quinazolinone compounds | UNIV HUNAN | 2013-11-27 | — | — | CN | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-0934934-A3 | Methods of preparing substituted 3-phenyl- and 3-pyridyl-4(3H)-quinazolinones and atropisomers thereof | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0934934-A2 | Methods of preparing substituted 3-phenyl- and 3-pyridyl-4(3H)-quinazolinones and atropisomers thereof | Pfizer Products Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | HPGD 4795/4885MAPT 3823/4885KDM4C 1357/4885 |
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | HPGD 641/4885MAPT 3912/4885KDM4C 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.